DK170922B1 - Cefaclorformulering med langvarig virkning - Google Patents

Cefaclorformulering med langvarig virkning Download PDF

Info

Publication number: DK170922B1
Authority: DK; Denmark
Prior art keywords: cefaclor; ccl; formulation; component; formulation according
Prior art date: 1983-06-15

Application number

DK291884A

Other languages

Danish (da)

English (en)

Other versions

DK291884D0 (da

Inventor

Teruo Sakamoto

Sadao Kawai

Kinzaburo Noda

Toyohiko Takeda

Hiroshi Kato

Original Assignee

Shionogi & Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1983-06-15

Filing date

1984-06-14

Publication date

1996-03-18

1984-06-14 Application filed by Shionogi & Co filed Critical Shionogi & Co

1984-06-14 Publication of DK291884D0 publication Critical patent/DK291884D0/da

1996-03-18 Application granted granted Critical

1996-03-18 Publication of DK170922B1 publication Critical patent/DK170922B1/da

Links

239000000203 mixture Substances 0.000 title claims abstract description 119
238000009472 formulation Methods 0.000 title claims abstract description 88
QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 title claims abstract description 43
229960005361 cefaclor Drugs 0.000 title claims abstract description 42
230000005923 long-lasting effect Effects 0.000 title claims description 10
239000008187 granular material Substances 0.000 claims description 81
239000011324 bead Substances 0.000 claims description 28
230000036765 blood level Effects 0.000 claims description 20
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 16
239000002775 capsule Substances 0.000 claims description 16
229920002261 Corn starch Polymers 0.000 claims description 15
239000008120 corn starch Substances 0.000 claims description 15
229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 13
239000001863 hydroxypropyl cellulose Substances 0.000 claims description 13
235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 13
238000009505 enteric coating Methods 0.000 claims description 11
239000002702 enteric coating Substances 0.000 claims description 11
235000010355 mannitol Nutrition 0.000 claims description 8
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 7
239000000654 additive Substances 0.000 claims description 7
229920002678 cellulose Polymers 0.000 claims description 7
235000010980 cellulose Nutrition 0.000 claims description 7
239000008101 lactose Substances 0.000 claims description 7
229920002472 Starch Polymers 0.000 claims description 6
-1 alkyl methacrylates Chemical class 0.000 claims description 5
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
229930006000 Sucrose Natural products 0.000 claims description 4
230000000996 additive effect Effects 0.000 claims description 4
235000019698 starch Nutrition 0.000 claims description 4
239000005720 sucrose Substances 0.000 claims description 4
229920003145 methacrylic acid copolymer Polymers 0.000 claims description 3
235000000346 sugar Nutrition 0.000 claims description 3
150000005846 sugar alcohols Chemical class 0.000 claims description 3
150000008163 sugars Chemical class 0.000 claims description 3
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
229940100445 wheat starch Drugs 0.000 claims description 2
239000007931 coated granule Substances 0.000 claims 1
238000006467 substitution reaction Methods 0.000 claims 1
230000003389 potentiating effect Effects 0.000 abstract description 2
208000035143 Bacterial infection Diseases 0.000 abstract 1
241001465754 Metazoa Species 0.000 abstract 1
208000022362 bacterial infectious disease Diseases 0.000 abstract 1
ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 28
238000002474 experimental method Methods 0.000 description 17
235000012054 meals Nutrition 0.000 description 15
239000011248 coating agent Substances 0.000 description 14
238000000576 coating method Methods 0.000 description 14
238000000034 method Methods 0.000 description 13
239000003814 drug Substances 0.000 description 12
244000005700 microbiome Species 0.000 description 12
229940079593 drug Drugs 0.000 description 11
238000012360 testing method Methods 0.000 description 11
239000000243 solution Substances 0.000 description 10
241000588724 Escherichia coli Species 0.000 description 9
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
239000000902 placebo Substances 0.000 description 8
229940068196 placebo Drugs 0.000 description 8
241000191967 Staphylococcus aureus Species 0.000 description 7
239000000546 pharmaceutical excipient Substances 0.000 description 7
239000000843 powder Substances 0.000 description 7
238000002360 preparation method Methods 0.000 description 7
238000010521 absorption reaction Methods 0.000 description 6
230000003115 biocidal effect Effects 0.000 description 6
230000000694 effects Effects 0.000 description 6
239000002054 inoculum Substances 0.000 description 6
239000002609 medium Substances 0.000 description 6
239000011230 binding agent Substances 0.000 description 5
239000001913 cellulose Substances 0.000 description 5
239000002552 dosage form Substances 0.000 description 5
229920001592 potato starch Polymers 0.000 description 5
230000001954 sterilising effect Effects 0.000 description 5
238000004659 sterilization and disinfection Methods 0.000 description 5
239000000758 substrate Substances 0.000 description 5
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 4
230000000844 anti-bacterial effect Effects 0.000 description 4
239000012530 fluid Substances 0.000 description 4
230000012010 growth Effects 0.000 description 4
238000005259 measurement Methods 0.000 description 4
229920000609 methyl cellulose Polymers 0.000 description 4
239000001923 methylcellulose Substances 0.000 description 4
235000010981 methylcellulose Nutrition 0.000 description 4
229960002900 methylcellulose Drugs 0.000 description 4
239000003094 microcapsule Substances 0.000 description 4
239000000454 talc Substances 0.000 description 4
229910052623 talc Inorganic materials 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
241000588722 Escherichia Species 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
229920001800 Shellac Polymers 0.000 description 3
239000008280 blood Substances 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
230000007012 clinical effect Effects 0.000 description 3
230000007423 decrease Effects 0.000 description 3
230000003111 delayed effect Effects 0.000 description 3
235000014113 dietary fatty acids Nutrition 0.000 description 3
239000000194 fatty acid Substances 0.000 description 3
229930195729 fatty acid Natural products 0.000 description 3
235000011187 glycerol Nutrition 0.000 description 3
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 3
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
229960003511 macrogol Drugs 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
229940106052 methylcellulose (25 cps) Drugs 0.000 description 3
239000004208 shellac Substances 0.000 description 3
229940113147 shellac Drugs 0.000 description 3
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 3
235000013874 shellac Nutrition 0.000 description 3
239000003826 tablet Substances 0.000 description 3
230000036962 time dependent Effects 0.000 description 3
229930186147 Cephalosporin Natural products 0.000 description 2
PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
230000000845 anti-microbial effect Effects 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
229940124587 cephalosporin Drugs 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
238000001035 drying Methods 0.000 description 2
230000029142 excretion Effects 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000011081 inoculation Methods 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
XNGIFLGASWRNHJ-UHFFFAOYSA-N o-dicarboxybenzene Natural products OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
239000008213 purified water Substances 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
238000004088 simulation Methods 0.000 description 2
210000000813 small intestine Anatomy 0.000 description 2
238000005507 spraying Methods 0.000 description 2
210000002784 stomach Anatomy 0.000 description 2
239000000126 substance Substances 0.000 description 2
238000010998 test method Methods 0.000 description 2
WKJGTOYAEQDNIA-IOOZKYRYSA-N (6r,7r)-7-[[(2r)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;hydrate Chemical compound O.C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 WKJGTOYAEQDNIA-IOOZKYRYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
101100439211 Caenorhabditis elegans cex-2 gene Proteins 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
108010059892 Cellulase Proteins 0.000 description 1
208000035484 Cellulite Diseases 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
229920003139 Eudragit® L 100 Polymers 0.000 description 1
229920003141 Eudragit® S 100 Polymers 0.000 description 1
229920003134 Eudragit® polymer Polymers 0.000 description 1
239000004606 Fillers/Extenders Substances 0.000 description 1
241000192125 Firmicutes Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
102220570135 Histone PARylation factor 1_L30D_mutation Human genes 0.000 description 1
238000012404 In vitro experiment Methods 0.000 description 1
241000196833 Kocuria rhizophila DC2201 Species 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000008272 agar Substances 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
230000003698 anagen phase Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
239000003429 antifungal agent Substances 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000007963 capsule composition Substances 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
229940106157 cellulase Drugs 0.000 description 1
230000036232 cellulite Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
229940106164 cephalexin Drugs 0.000 description 1
150000001780 cephalosporins Chemical class 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000005094 computer simulation Methods 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
238000001816 cooling Methods 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
238000012136 culture method Methods 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000003113 dilution method Methods 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
239000007888 film coating Substances 0.000 description 1
238000009501 film coating Methods 0.000 description 1
238000009477 fluid bed granulation Methods 0.000 description 1
239000012520 frozen sample Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
229960000367 inositol Drugs 0.000 description 1
229940090589 keflex Drugs 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
150000002605 large molecules Chemical class 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
238000002483 medication Methods 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
230000000979 retarding effect Effects 0.000 description 1
CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
239000003270 steroid hormone Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
238000005550 wet granulation Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Cephalosporin Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

DK291884A 1983-06-15 1984-06-14 Cefaclorformulering med langvarig virkning DK170922B1 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP10828983		1983-06-15
JP58108289A JPS601128A (ja)	1983-06-15	1983-06-15	作用持続型セフアクロル製剤

Publications (2)

Publication Number	Publication Date
DK291884D0 DK291884D0 (da)	1984-06-14
DK170922B1 true DK170922B1 (da)	1996-03-18

Family

ID=14480890

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK291884D DK291884A (da)	1983-06-15	1984-06-14	Cefaclorformulering med langvarig virkning
DK291884A DK170922B1 (da)	1983-06-15	1984-06-14	Cefaclorformulering med langvarig virkning

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK291884D DK291884A (da)	1983-06-15	1984-06-14	Cefaclorformulering med langvarig virkning

Country Status (23)

Country	Link
US (1)	US4713247A (fr)
EP (1)	EP0129382B1 (fr)
JP (1)	JPS601128A (fr)
KR (1)	KR910004573B1 (fr)
AT (1)	ATE56869T1 (fr)
AU (1)	AU568654B2 (fr)
BG (1)	BG60261B1 (fr)
CA (1)	CA1213218A (fr)
DD (1)	DD216163A5 (fr)
DE (1)	DE3483282D1 (fr)
DK (2)	DK291884A (fr)
ES (1)	ES8602407A1 (fr)
FI (1)	FI84556C (fr)
GB (1)	GB2141342B (fr)
GR (1)	GR81598B (fr)
HU (1)	HU193434B (fr)
IE (1)	IE58278B1 (fr)
IL (1)	IL72083A (fr)
NZ (1)	NZ208345A (fr)
PH (1)	PH19902A (fr)
PT (1)	PT78699B (fr)
RO (1)	RO88924A (fr)
ZA (1)	ZA844357B (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5229132A (en) *	1985-02-22	1993-07-20	Grimberg Georges Serge	Non-absorbable gastrointestinal medicament provided for treating the two levels of the digestive tract at the same time
JPS61210025A (ja) *	1985-03-14	1986-09-18	Teisan Seiyaku Kk	安定化された抗生物質複合顆粒製剤
AU591248B2 (en) *	1986-03-27	1989-11-30	Kinaform Technology, Inc.	Sustained-release pharaceutical preparation
JPS62226926A (ja) *	1986-03-27	1987-10-05	Teisan Seiyaku Kk	持続性複合顆粒剤
JPH0714863B2 (ja) *	1986-06-02	1995-02-22	忠生白石	時差溶解性の入浴剤
CA1316110C (fr) *	1987-02-27	1993-04-13	Eli Lilly And Company	Formulations de matrices a effet prolonge
US4968508A (en) *	1987-02-27	1990-11-06	Eli Lilly And Company	Sustained release matrix
BE1002079A4 (fr) *	1988-07-01	1990-06-19	S M B Lab	Composition pharmaceutique d'erythromycine a liberation prolongee, sa preparation et son utilisation.
US5133974A (en) *	1989-05-05	1992-07-28	Kv Pharmaceutical Company	Extended release pharmaceutical formulations
US5122384A (en) *	1989-05-05	1992-06-16	Kv Pharmaceutical Company	Oral once-per-day organic nitrate formulation which does not induce tolerance
CA2085342A1 (fr) *	1990-06-14	1991-12-15	Milton R. Kaplan	Suspension aqueuse stable de medicament
GB9318641D0 (en) *	1993-09-08	1993-10-27	Edko Trading Representation	Compositions
ES2079327B1 (es) *	1994-12-13	1996-08-01	Lilly Sa	Formulaciones farmaceuticas de cefaclor.
WO1997033569A1 (fr) *	1996-03-13	1997-09-18	LABTEC Gesellschaft für technologische Forschung und Entwicklung mbH	Preparation medicamenteuse pour inhibiteurs de l'enzyme de conversion de l'angiotensine (ace)
US5948440A (en) *	1997-12-17	1999-09-07	Ranbaxy Laboratories Limited	Modified release matrix formulation of cefaclor and cephalexin
ZA98728B (en) *	1998-01-29	1998-10-28	Ranbaxy Lab Ltd	Modified release matrix formulations of cefactor and cephalexin
KR100296413B1 (ko) *	1998-04-01	2001-11-14	김선진	세파클러함유서방성정제
WO2000059479A1 (fr) *	1999-04-06	2000-10-12	Pharmaquest Ltd.	Forme posologique pharmaceutique permettant l'administration intermittente de methylphenidate
US20030170181A1 (en) *	1999-04-06	2003-09-11	Midha Kamal K.	Method for preventing abuse of methylphenidate
AU4441899A (en) *	1999-05-14	2000-12-05	Eli Lilly And Company	Process for preparing pharmaceutical bulk material having uniform dissolution
US6596307B1 (en)	1999-06-15	2003-07-22	Eli Lilly And Company	Process for preparing pharmaceutical bulk material having uniform dissolution
US6991807B2 (en) *	2000-02-24	2006-01-31	Advancis Pharmaceutical, Corp.	Antibiotic composition
EP1257255A4 (fr) *	2000-02-24	2008-07-30	Advancis Pharmaceutical Corp	Produit therapeutique, son application et sa formulation
US7025989B2 (en) *	2000-02-24	2006-04-11	Advancis Pharmaceutical Corp.	Multiple-delayed released antibiotic product, use and formulation thereof
WO2001062195A1 (fr) *	2000-02-24	2001-08-30	Advancis Pharmaceutical Corporation	Compositions antibiotiques et antifongiques
AU3986901A (en) *	2000-02-24	2001-09-03	Advancis Pharmaceutical Corp	Antibiotic composition with inhibitor
EP1353651A2 (fr) *	2001-01-18	2003-10-22	Natco Pharma Limited	Compositions pharmaceutiques a liberation lente contenant des antibiotiques beta-lactame
JP2005526059A (ja) *	2002-03-07	2005-09-02	アドバンシスファーマスーティカルコーポレイション	抗生物質組成物
WO2003094899A1 (fr) *	2002-05-09	2003-11-20	Diffucap-Chemobras Química E Farmacéutica, Ltda.	Nouveau procede pour la preparation de compositions a liberation programmee contenant (s) -1- [n-[1-(ethoxycarbonyl)-3-phenylpropyl]-l-alanyl]-l-proline, et produit ainsi obtenu
AU2004258953B2 (en) *	2003-07-21	2011-02-10	Shionogi, Inc.	Antibiotic product, use and formulation thereof
AU2004258949B2 (en) *	2003-07-21	2011-02-10	Shionogi, Inc.	Antibiotic product, use and formulation thereof
JP2006528185A (ja) *	2003-07-21	2006-12-14	アドバンシスファーマスーティカルコーポレイション	抗生物質製剤、その使用法及び作成方法
US8062672B2 (en) *	2003-08-12	2011-11-22	Shionogi Inc.	Antibiotic product, use and formulation thereof
AU2004270170B2 (en) *	2003-08-29	2011-01-27	Shionogi, Inc.	Antibiotic product, use and formulation thereof
CA2538064C (fr) *	2003-09-15	2013-12-17	Advancis Pharmaceutical Corporation	Antibiotique, son utilisation et sa formulation
WO2005030178A1 (fr) *	2003-09-30	2005-04-07	Lupin Ltd.	Formulation de liberation etendue d'antibiotiques de type beta-lactame
AU2006235483B2 (en) *	2005-04-12	2010-11-25	Elan Pharma International Limited	Controlled release compositions comprising a cephalosporin for the treatment of a bacterial infection
US20060287212A1 (en) *	2005-06-02	2006-12-21	Novozymes A/S	Blends of inactive particles and active particles
JP2008545841A (ja)	2005-06-02	2008-12-18	ノボザイムスアクティーゼルスカブ	不活性粒子及び活性粒子のブレンド
TWI489984B (zh)	2006-08-04	2015-07-01	Wyeth Corp	用於非經腸道傳輸化合物之配方及其用途
BRPI1007855B1 (pt)	2009-05-19	2020-03-10	Celgene Corporation	Formas de dosagem oral compreendendo 4-amino-2-(2,6-dioxopiperidina-3-il)isoindolina-1,3-diona
KR20140107540A (ko) *	2011-12-19	2014-09-04	샐릭스 파마슈티컬스 리미티드	메틸날트렉손의 경구 조성물을 사용하는 오피오이드 유발성 변비의 치료 및 예방 방법
CA2936740C (fr)	2014-10-31	2017-10-10	Purdue Pharma	Methodes et compositions destinees au traitement du trouble de deficit d'attention
CN104688701A (zh) *	2015-03-20	2015-06-10	江苏亚邦强生药业有限公司	一种头孢克洛片剂及其制备方法
US10722473B2 (en)	2018-11-19	2020-07-28	Purdue Pharma L.P.	Methods and compositions particularly for treatment of attention deficit disorder
CN110408670A (zh) *	2019-08-19	2019-11-05	苏州盛达药业有限公司	一种酶催化合成头孢克洛的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2738303A (en) *	1952-07-18	1956-03-13	Smith Kline French Lab	Sympathomimetic preparation
US3906086A (en) *	1971-07-19	1975-09-16	Richard G Powers	Timed-release aspirin
JPS52139713A (en) *	1976-05-13	1977-11-21	Shionogi & Co Ltd	Sustained release cefalexin preparations
US4250166A (en) *	1977-05-27	1981-02-10	Shionogi & Co., Ltd.	Long acting preparation of cefalexin for effective treatments of bacterial infection sensitive to cefalexin
GR74995B (fr) *	1980-08-27	1984-07-12	Ciba Geigy Ag
JPS5826816A (ja) *	1981-08-11	1983-02-17	Teisan Seiyaku Kk	球形顆粒からなる持続性複合顆粒剤

1983
- 1983-06-15 JP JP58108289A patent/JPS601128A/ja active Granted
1984
- 1984-05-30 US US06/615,242 patent/US4713247A/en not_active Expired - Lifetime
- 1984-05-31 NZ NZ208345A patent/NZ208345A/en unknown
- 1984-06-04 GR GR74913A patent/GR81598B/el unknown
- 1984-06-06 PT PT78699A patent/PT78699B/pt unknown
- 1984-06-08 IE IE144484A patent/IE58278B1/en not_active IP Right Cessation
- 1984-06-08 DE DE8484303908T patent/DE3483282D1/de not_active Expired - Fee Related
- 1984-06-08 ZA ZA844357A patent/ZA844357B/xx unknown
- 1984-06-08 GB GB08414633A patent/GB2141342B/en not_active Expired
- 1984-06-08 AT AT84303908T patent/ATE56869T1/de not_active IP Right Cessation
- 1984-06-08 EP EP84303908A patent/EP0129382B1/fr not_active Expired - Lifetime
- 1984-06-11 PH PH30800A patent/PH19902A/en unknown
- 1984-06-13 BG BG065844A patent/BG60261B1/bg unknown
- 1984-06-13 IL IL72083A patent/IL72083A/xx unknown
- 1984-06-13 FI FI842406A patent/FI84556C/fi not_active IP Right Cessation
- 1984-06-13 RO RO84114861A patent/RO88924A/fr unknown
- 1984-06-14 DK DK291884D patent/DK291884A/da unknown
- 1984-06-14 DK DK291884A patent/DK170922B1/da not_active IP Right Cessation
- 1984-06-14 HU HU842312A patent/HU193434B/hu not_active IP Right Cessation
- 1984-06-15 DD DD84264197A patent/DD216163A5/de unknown
- 1984-06-15 KR KR1019840003359A patent/KR910004573B1/ko not_active Expired
- 1984-06-15 AU AU29418/84A patent/AU568654B2/en not_active Ceased
- 1984-06-15 ES ES533901A patent/ES8602407A1/es not_active Expired
- 1984-06-15 CA CA000456659A patent/CA1213218A/fr not_active Expired

Also Published As

Publication number	Publication date
GB2141342B (en)	1986-11-12
DK291884A (da)	1984-12-16
US4713247A (en)	1987-12-15
ATE56869T1 (de)	1990-10-15
HUT34692A (en)	1985-04-28
RO88924A (fr)	1986-04-30
FI84556B (fi)	1991-09-13
ZA844357B (en)	1985-06-26
FI842406L (fi)	1984-12-16
DE3483282D1 (de)	1990-10-31
IE841444L (en)	1984-12-15
ES533901A0 (es)	1985-12-01
GR81598B (fr)	1984-12-11
IL72083A0 (en)	1984-10-31
PT78699A (pt)	1985-01-01
DD216163A5 (de)	1984-12-05
AU2941884A (en)	1984-12-20
AU568654B2 (en)	1988-01-07
HU193434B (en)	1987-10-28
BG60261B2 (en)	1994-03-31
PT78699B (en)	1986-07-15
BG60261B1 (bg)	1994-03-31
EP0129382B1 (fr)	1990-09-26
IL72083A (en)	1987-10-30
FI842406A0 (fi)	1984-06-13
FI84556C (fi)	1991-12-27
EP0129382A2 (fr)	1984-12-27
IE58278B1 (en)	1993-08-25
ES8602407A1 (es)	1985-12-01
EP0129382A3 (en)	1986-07-09
NZ208345A (en)	1986-12-05
CA1213218A (fr)	1986-10-28
JPS6232166B2 (fr)	1987-07-13
GB8414633D0 (en)	1984-07-11
KR850000242A (ko)	1985-02-26
GB2141342A (en)	1984-12-19
PH19902A (en)	1986-08-13
JPS601128A (ja)	1985-01-07
DK291884D0 (da)	1984-06-14
KR910004573B1 (ko)	1991-07-06

Legal Events

Date	Code	Title	Description
1996-03-18	B1	Patent granted (law 1993)
2004-02-02	PBP	Patent lapsed	Country of ref document: DK

Publication	Publication Date	Title
DK170922B1 (da)	1996-03-18	Cefaclorformulering med langvarig virkning
TW576743B (en)	2004-02-21	Extended release formulations of erythromycin derivatives
US4250166A (en)	1981-02-10	Long acting preparation of cefalexin for effective treatments of bacterial infection sensitive to cefalexin
NZ201008A (en)	1985-11-08	Oral preparations containing dipyridamole and at least 5 molar equivalents of orally acceptable acidic excipient
CZ455990A3 (en)	1997-08-13	Pharmaceutical application system and process for producing thereof
PL188834B1 (pl)	2005-04-29	Farmaceutyczne formulacje zawierające tramadol lub jego fizjologicznie akceptowane sole oraz sposóbwytwarzania tych formulacji
MX2010009704A (es)	2010-12-20	Composiciones farmaceuticas de liberacion modifcada que comprenden micofenolato y procesos de estas.
PH27176A (en)	1993-04-02	Pharmaceutical compositions containing dipyridamole or mopidamole and O-acetylsalicyclic acid or the physiologically acceptable salts thereof
CN101006985A (zh)	2007-08-01	药用组合物
RO116997B1 (ro)	2001-09-28	Procedeu pentru prepararea unei formulări de tabletă
NZ202140A (en)	1985-12-13	Delayed release nitrofurantoin tablets
EP1154762B1 (fr)	2003-11-05	Compositions de capsules pharmaceutiques contenant de la loratadine et de la pseudoephedrine
EP0418597A2 (fr)	1991-03-27	Compositions pharmaceutiques à libération contrôlée contenant des inhibiteurs de l'anhydrase carbonique à partir de granules sphériques sous forme d'une dose unitaire orale en capsule
US20230218626A1 (en)	2023-07-13	Methods and compositions to support the growth or maintenance of oxygen-sensitive bacteria in the gastrointestinal tract
CZ287563B6 (en)	2000-12-13	Pharmaceutical preparations for treating hyperglycemia
AU668267B2 (en)	1996-04-26	Method for preventing and treating disturbances of intestinal mucous membrane
CN118284415B (zh)	2026-01-06	一种达罗他胺药物组合物及其制备方法和用途
US5091191A (en)	1992-02-25	Pharmaceutical composition with improved dissolution property
CN112057429B (zh)	2023-04-07	雷西纳德控释药物组合物
CN102397278A (zh)	2012-04-04	一种抗高血压药物组合物
JP2022518678A (ja)	2022-03-16	炎症性腸疾患の処置のための治療用配合物及び組成物
JP2022518677A (ja)	2022-03-16	炎症性腸疾患の処置のための治療用配合物及び組成物（ｉｉ）
RU2468802C2 (ru)	2012-12-10	Комбинированная противотуберкулезная композиция
KR100212960B1 (ko)	1999-08-02	경구용 복합제제
RU2413517C1 (ru)	2011-03-10	Комбинированная противотуберкулезная композиция